News
Beyond the Scale: Do GLP-1RAs Offer More Than Weight Loss in PsA?
Over 70% of patients with PsA struggle with excess weight, amplifying synovio-entheseal inflammation and blunting biologic response. The rapid uptake of GLP-1RAs in rheumatology has raised an urgent mechanistic question: are clinical gains in PsA driven purely by weight reduction, or do these agents carry intrinsic anti-inflammatory properties? EULAR 2026 offered six abstracts that together illuminate, without fully resolving, this question.
Diet as a DMARD? The Evidence Is Still Hard to Swallow
Dietary interventions are rarely taken as seriously as pharmacological therapies in rheumatology. Yet patients ask about them constantly, and an increasing number of studies suggest that nutrition may influence disease outcomes. Two randomized controlled trials presented at EULAR 2026 add to this growing literature in PsA and RA. However, before we start prescribing Mediterranean diets, the data deserve a closer look.
JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal
Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings.
New Insights in Gout Clinical Management
EULAR 2026 Press Release
EULAR – The European Alliance of Associations for Rheumatology – held its 2026 annual Congress in London, where gout was high on the agenda.
CAR-T Cell Therapies in Refractory RMD
EULAR 2026 Press Release
Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare.
From Skepticism to Reconsideration: 4‑Year CAR‑T Outcomes in Lupus
Chimeric antigen receptor (CAR) T‑cell therapy, long established in hematologic malignancies, is now emerging as a transformative approach in systemic lupus erythematosus (SLE), a disease historically managed with chronic immunosuppression.
Progress of biologics/targeted therapy in SLE
We are in a transformative era in SLE which generates excitement to both physicians and people living with lupus. We now have four licensed biologics/targeted therapies (i.e., belimumab, voclosporin and obinutuzumab for active lupus nephritis, and belimumab and anifrolumab for active non-renal SLE). Moreover, many other agents with different mode of action and administration are in late phase trials. This article previews some data being presented at EULAR 2026 Congress in London.
A Field Whose Time Has Come: Launching the EULAR Study Group on Geriatric Rheumatology
A substantial portion of patients seen in rheumatology clinics are now older adults living with multimorbidity, polypharmacy, frailty, cognitive impairment, functional limitation, and competing health priorities. This week at EULAR 2026 in London, the EULAR Study Group on Geriatric Rheumatology holds its inaugural meeting. The launch marks an important step for a field that has been visible in clinical practice, but less visible in professional structures.
EULAR 2026: Industry Press Releases
Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will directly shape treatment decisions in rheumatic diseases.
Rheumatology Shortage Cliff in Australia & USA
Australia is facing a deepening rheumatology manpower crisis with direct parallels to the situation in the United States.
ACPA and the Transition from Arthralgia to Rheumatoid Arthritis
MedPage Today
